AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

DACLATASVIR 60 Mg ;

11 registrations across 1 African market— 11 active

Markets with DACLATASVIR 60 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Dacvirotal
Film Coated Tablets
🇪🇬EgyptFUTURE PHARMACEUTICAL INDUSTRIES-EGYPTactive
Dacladazin 60 mg
Film Coated Tablets
🇪🇬EgyptEgyptian International Pharmaceutical Industries Company (EIPICO)active
Dacladova 60mg
Film Coated Tablets
🇪🇬EgyptHikma Pharmaceuticals industriesactive
Andodaclata
Film Coated Tablets
🇪🇬Egyptal andalous for pharmaceutical industriesactive
Replitasvir
Film Coated Tablets
🇪🇬EgyptAmoun Pharmaceutical Companyactive
Dacvirotal
Film Coated Tablets
🇪🇬EgyptFUTURE PHARMACEUTICAL INDUSTRIES-EGYPTactive
Dacladazin 60 mg
Film Coated Tablets
🇪🇬EgyptEgyptian International Pharmaceutical Industries Company (EIPICO)active
Dacladova 60mg
Film Coated Tablets
🇪🇬EgyptHikma Pharmaceuticals industriesactive
Andodaclata
Film Coated Tablets
🇪🇬Egyptal andalous for pharmaceutical industriesactive
Daclahepex
Film Coated Tablets
🇪🇬EgyptGlobal Pharmaceutical Industriesactive
Replitasvir
Film Coated Tablets
🇪🇬EgyptAmoun Pharmaceutical Companyactive

DACLATASVIR 60 Mg ; in Africa — Regulatory Overview

DACLATASVIR 60 Mg ; is registered across 1 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 11 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.